NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

February 6, 2024

https://www.globenewswire.com/news-release/2024/02/06/2824316/0/en/NeuroStar-TMS-Patient-Access-Expands-Through-Lucet-Health-Policy-Update.html

MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation (TMS), such as NeuroStar® Advanced Therapy. The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility.

Read more at globenewswire.com

Related news for (STIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.